In a market note, the investment firm said it downgraded Novo Nordisk A/S (NYSE:NVO) to “neutral” from “buy” previously and ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0815 GMT – Sanofi’s higher costs overshadow an upgrade to its ...

Eli Lilly (LLY) stock in focus as its diabetes drug Mounjaro causes heart benefits suceeding in a late-stage trial versus its ...

Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Danish leader will face a challenging landscape among competitors ...

Aggressive social media marketing by influencers has fuelled a surge in over-the-counter use of the diabetes and obesity ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Novo Nordisk's launch of NovoCare is showing signs of boosting Wegovy's sales, and the E.U.-U.S. trade deal adds stability ...

U.S.-listed shares of Novo Nordisk fell sharply for a second straight day Wednesday, this time after Bank of America ...

Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...

In this week’s edition of InnovationRx, we look at Halle Berry’s menopause startup, Ambience Healthcare’s $243 million ...